Financial Comparison: Longevity Health (XAGE) vs. Its Competitors

Insider and Institutional Ownership

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 29.0% of Longevity Health shares are held by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Longevity Health has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Longevity Health’s competitors have a beta of 1.76, indicating that their average stock price is 76% more volatile than the S&P 500.

Valuation & Earnings

This table compares Longevity Health and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Longevity Health	$1.05 million	-$10.37 million	-0.07
Longevity Health Competitors	$59.54 million	-$32.15 million	3.99

Longevity Health’s competitors have higher revenue, but lower earnings than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Longevity Health and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Longevity Health Competitors	-672.41%	-133.75%	-59.01%

Summary

Longevity Health competitors beat Longevity Health on 5 of the 9 factors compared.

Longevity Health Company Profile

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.